CVSNYSERetail-Drug Stores and Proprietary StoresFiscal year ends December 31
CVS HEALTH Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$92.68+0.32 (+0.35%)
Close on Oct 19, 2026
- Market cap
- $119.28B
- P/E (TTM)
- 24.6
- Dividend yield
- 2.87%
CVS HEALTH Corp revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Health Services | $51.80B | $48.24B | $51.24B | $49.27B | $46.45B | $43.46B | $47.02B | $44.13B | $42.17B | $40.29B | $49.15B | $46.89B | 48.8% | +11.5% |
| Health Care Benefits | $37.54B | $35.97B | $36.29B | $35.99B | $36.26B | $34.81B | $32.96B | $33.00B | $32.48B | $32.24B | $26.73B | $26.30B | 35.4% | +3.5% |
| Pharmacy & Consumer Wellness | $33.82B | $31.99B | $37.66B | $36.21B | $33.58B | $31.91B | $33.51B | $32.42B | $29.84B | $28.73B | $31.19B | $28.87B | 31.9% | +0.7% |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Products | $66.22B | $62.23B | $67.04B | $64.59B | $60.61B | $57.67B | $61.91B | $59.67B | $56.21B | $53.72B | $65.15B | $61.30B | 62.4% | +9.3% |
| Services | $4.12B | $3.84B | $4.04B | $3.93B | $3.63B | $3.58B | $4.13B | $4.28B | $3.96B | $3.87B | $3.32B | $3.53B | 3.9% | +13.6% |
By region
From the segment and revenue-disaggregation notes of Cvs Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.